Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Adipose stromal vascular fraction attenuates T H 1 cell-mediated pathology in a model of multiple sclerosis.

Bowles AC., Wise RM., Gerstein BY., Thomas RC., Ogelman R., Manayan RC.

Animal Study on Neuroinflammation, Immune Modulation, Autoimmune Research, published in J Neuroinflammation (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Neuroinflammation (2018)
Country
England
Reported sample size
—
Source database
PubMed
PMID
29534751
PMCID
PMC5850918
DOI
10.1186/s12974-018-1099-3
Citations
16

Abstract (original English)

Background The therapeutic efficacy of adipose-derived stem cells (ASCs) has been investigated for numerous clinical indications, including autoimmune and neurodegenerative diseases. Less is known using the crude adipose product called stromal vascular fraction (SVF) as therapy, although our previous studies demonstrated greater efficacy at late-stage disease compared to ASCs in the experimental autoimmune encephalomyelitis (EAE) mouse, a model of multiple sclerosis. In this study, SVF cells and ASCs were administered during the pathogenic progression, designated as early disease, to elucidate immunomodulatory mechanisms when high immune cell activities associated with autoimmune signaling occur. These implications are essential for clinical translation when considering timing of administration for cell therapies. Methods We investigated the effects of SVF cells and ASCs by analyzing the spleens, peripheral blood, and central nervous system tissues throughout the course of EAE disease following administration of SVF cells, ASCs, or vehicle. In vitro, immunomodulatory potentials of SVF cells and ASCs were measured when exposed to EAE-derived splenocytes. Results Interestingly, treatment with SVF cells and ASCs transiently enhanced the severity of disease directly after administration, substantiating this critical immunomodulatory signaling. More importantly, it was only the EAE

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsAntigens, NeoplasmCoculture TechniquesDisease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalFemaleForkhead Transcription FactorsGene Expression RegulationImmunologic Factors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research